<Disease><Name>3-METHYLGLUTACONIC ACIDURIA (TYPE III)</Name><Synonym>COSTEFF SYNDROME; OPTIC ATROPHY PLUS SYNDROME;MGA3</Synonym><OMIM><Number>258501</Number><URL>http://omim.org/entry/258501</URL></OMIM><Orphanet><Number>67047</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=67047</URL></Orphanet><Protein><Number>Optic atrophy 3 protein</Number><URL>http://www.uniprot.org/uniprot/Q9H6K4</URL></Protein><ExPASy><Number /><URL /></ExPASy><Gene>19q13.2-13.3</Gene><ICD>E71.1</ICD><Summary>rare (&lt;1:200000) ;autosomal recessive ;mutation in the OPA3 gene ;Most of the patients are of Iraqi-Jewish origin, mutation in the OPA3 gene was identified.</Summary><Symptoms><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1945</id><symptom>chorea or athetosis</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3460</id><symptom>cognitive impairment / cognitive dysfunction</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2164</id><symptom>dysarthria</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1969</id><symptom>extrapyramidal signs</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2261</id><symptom>hyperreflexia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2213</id><symptom>MRI, brain, abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1917</id><symptom>neurological deterioration / neurologic deterioration</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1723</id><symptom>nystagmus</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1739</id><symptom>optic atrophy</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2089</id><symptom>Organic acids, urine</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1974</id><symptom>spastic diplegia/quadriplegia/tetraplegia</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>3888</id><symptom>spastic paraplegia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1874</id><symptom>speech development, delayed, abnormal</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>1576</id><name>3-Methylglutaconic acid</name><specimen>urine</specimen><value>increased</value><min>3.40</min><max>9.50</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1662</id><name>3-Methylglutaric acid</name><specimen>urine</specimen><value>increased</value><min>2.60</min><max>3.60</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1709</id><name>3-Methylglutaconic acid</name><specimen>urine</specimen><value>increased</value><min>17.00</min><max>26.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>83</id><name>3-Methylglutaconic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>1342</id><name>3-Methylglutaconic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>1343</id><name>3-Methylglutaconic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1156</id><name>3-Methylglutaconic acid</name><specimen>amnion fluid</specimen><value>increased</value><min>    </min><max>    </max><unit>no data</unit><age>adult</age><method /><comment /></metabolite><metabolite><id>636</id><name>3-Methylglutaric acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>6.00</max><unit>mmol/mol creatinine</unit><age>ALL</age><method>GCMS</method><comment /></metabolite><metabolite><id>637</id><name>3-Methylglutaric acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>adolescence</age><method /><comment /></metabolite><metabolite><id>84</id><name>3-Methylglutaric acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>7.00</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>633</id><name>3-Methylglutaric acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>9.70</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>635</id><name>3-Methylglutaric acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>2.80</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>3449</id><title>Atypical presentation of Costeff syndrome-severe psychomotor involvement and electrical status epilepticus during slow wave sle</title><author>Carmi N,</author><journal>Eur J Paediatr Neurol</journal><year>2015</year><book /><volume>19</volume><number>6</number><pages>733-736</pages><co_aut>et al.</co_aut></literature><literature><id>3450</id><title>The neuropsychological profile of patients with 3-methylglutaconic aciduria type III, Costeff syndrome</title><author>Sofer S,</author><journal>Am J Med Genet B Neuropsychiatr Genet</journal><year>2015</year><book /><volume>168</volume><number>3</number><pages>197-203</pages><co_aut>et al.</co_aut></literature><literature><id>3451</id><title>Costeff syndrome: clinical features and natural history</title><author>Yahalom G,</author><journal>J Neurol</journal><year>2014</year><book /><volume>261</volume><number>12</number><pages>2275-2282</pages><co_aut>et al.</co_aut></literature><literature><id>3452</id><title>Metabolic biology of 3-methylglutaconic acid-uria: a new perspective</title><author>Su B,</author><journal>J Inherit Metab Dis</journal><year>2014</year><book /><volume>37</volume><number>3</number><pages>359-368</pages><co_aut>Ryan RO</co_aut></literature><literature><id>3062</id><title>The 3-methylglutaconic acidurias: whats new?</title><author>Wortmann SB,</author><journal>J Inher Metab Dis</journal><year>2012</year><book /><volume>35</volume><number>1</number><pages>13-22</pages><co_aut>et al.</co_aut></literature><literature><id>2867</id><title>Costeff optic atrophy syndrome: New clinical case and novel molecular findings</title><author>Ho G</author><journal>J Inherit Metab Dis</journal><year>2008</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Walter JH, Christodoulou J</co_aut></literature><literature><id>2600</id><title>[Costeff syndrome: a syndrome that was described in Israel and the responsible gene discovered by an Israeli doctor]</title><author>Fink N</author><journal>Harefuah</journal><year>2006</year><book /><volume>145</volume><number>6</number><pages>402-403</pages><co_aut>Mouallem M</co_aut></literature><literature><id>1219</id><title>3-Methylglutaconic aciduria type III in a non-Iraqi-Jewish kindred: clinical and molecular findings</title><author>Kleta R</author><journal>Mol Genet Metab</journal><year>2002</year><book /><volume>76</volume><number>3</number><pages>201-206</pages><co_aut>et al.</co_aut></literature><literature><id>1527</id><title>Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OP</title><author>Anikster Y</author><journal>Am J Hum Genet</journal><year>2001</year><book /><volume>69</volume><number>6</number><pages>1218-1224</pages><co_aut>et al.</co_aut></literature><literature><id>1528</id><title>18Fluoro-2-deoxyglucose (18FDG) PET scan of the brain in type IV 3-methylglutaconic aciduria: clinical and MRI correlations</title><author>Al-Essa M</author><journal>Brain Dev</journal><year>1999</year><book /><volume>21</volume><number>1</number><pages>24-29</pages><co_aut>et al.</co_aut></literature><literature><id>1218</id><title>3-Methyl glutaconic aciduria in Iraqi Jewish children may be misdiagnosed as cerebral palsy</title><author>Straussberg R</author><journal>Neuropediatrics</journal><year>1998</year><book /><volume>29</volume><number>1</number><pages>54-56</pages><co_aut>Brand N, Gadoth N</co_aut></literature><literature><id>1529</id><title>Combined 3-methylglutaconic and 3-hydroxy-3-methylglutaric aciduria with endocardial fibroelastosis and dilatative cardiomyopath</title><author>Ruesch S</author><journal>Enzyme Protein</journal><year>1996</year><book /><volume>49</volume><number>0</number><pages>321-329</pages><co_aut>et al.</co_aut></literature><literature><id>332</id><title>Behr syndrome [letter]</title><author>Lerman-Sagie T</author><journal>Pediatr Neurol</journal><year>1995</year><book /><volume>12</volume><number>1</number><pages>90</pages><co_aut /></literature><literature><id>331</id><title>3-Methylglutaconic aciduria in the Iraqi-Jewish optic atrophy plus (Costeff) syndrome</title><author>Elpeleg ON</author><journal>Dev Med Child Neurol</journal><year>1994</year><book /><volume>36</volume><number>2</number><pages>167-172</pages><co_aut>et al.</co_aut></literature><literature><id>320</id><title>3-Methylglutaconic aciduria in optic atrophy plus</title><author>Costeff H</author><journal>Ann Neurol</journal><year>1993</year><book /><volume>33</volume><number>1</number><pages>103-104</pages><co_aut>et al.</co_aut></literature><literature><id>321</id><title>Behrs syndrome and 3-methylglutaconic aciduria</title><author>Sheffer RN</author><journal>Am J Ophthalmol</journal><year>1992</year><book /><volume>114</volume><number>4</number><pages>494-497</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>